A tailored decision aid improves understanding of lung cancer screening in people with HIV.

HIV Lung Cancer Screening Shared Decision Making Tobacco

Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 04 04 2024
revised: 21 06 2024
accepted: 11 07 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

People with HIV are at increased risk for lung cancer and multimorbidity, complicating the balance of risks and benefits of lung cancer screening. We previously adapted Decision Precision (screenlc.com) to guide shared decision-making for lung cancer screening in people with HIV. Does an HIV-adapted and personally tailored decision aid improve shared decision-making regarding lung cancer screening in people with HIV as measured by knowledge, decisional conflict, and acceptability? This was a single-arm pilot trial of the decision aid in 40 participants with HIV eligible for lung cancer screening. The decision aid included personalized screening recommendations and HIV-specific, five-year risk estimates of lung cancer and all-cause mortality. Participants reviewed the decision aid at shared decision-making visits and completed pre- and post-visit surveys with measures of knowledge about lung cancer screening, acceptability, and decisional conflict. The 40 enrolled participants were a median 62 years old and 60% were currently smoking with median five-year risks of lung cancer and all-cause mortality of 2.0% (IQR 1.4-3.3%) and 4.1% (IQR 3.3-7.9%). Personalized recommendations included "Encourage Screening" for 53% of participants and "Preference Sensitive" recommendations for the remainder. Participants showed improvement in two validated knowledge measures with relative improvement of 60% (p<0.001) on the LCS-12 and 27% (p<0.001) on the LKS-7, with significant improvement on questions regarding false-positive and false-negative findings, incidental findings, lung cancer-specific mortality benefit, and the possible harms of screening. Participants reported low scores on the decisional conflict scale (median score 0, IQR 0-5) and high acceptability. Ninety percent ultimately underwent screening within one month of the visit. This HIV-adapted and personally tailored decision aid improved participants' knowledge of risks, benefits, and characteristics of screening with low decisional conflict and high acceptability. This decision aid can enable high-quality shared decision-making in this high-risk population.

Sections du résumé

BACKGROUND BACKGROUND
People with HIV are at increased risk for lung cancer and multimorbidity, complicating the balance of risks and benefits of lung cancer screening. We previously adapted Decision Precision (screenlc.com) to guide shared decision-making for lung cancer screening in people with HIV.
RESEARCH QUESTION OBJECTIVE
Does an HIV-adapted and personally tailored decision aid improve shared decision-making regarding lung cancer screening in people with HIV as measured by knowledge, decisional conflict, and acceptability?
STUDY DESIGN AND METHODS METHODS
This was a single-arm pilot trial of the decision aid in 40 participants with HIV eligible for lung cancer screening. The decision aid included personalized screening recommendations and HIV-specific, five-year risk estimates of lung cancer and all-cause mortality. Participants reviewed the decision aid at shared decision-making visits and completed pre- and post-visit surveys with measures of knowledge about lung cancer screening, acceptability, and decisional conflict.
RESULTS RESULTS
The 40 enrolled participants were a median 62 years old and 60% were currently smoking with median five-year risks of lung cancer and all-cause mortality of 2.0% (IQR 1.4-3.3%) and 4.1% (IQR 3.3-7.9%). Personalized recommendations included "Encourage Screening" for 53% of participants and "Preference Sensitive" recommendations for the remainder. Participants showed improvement in two validated knowledge measures with relative improvement of 60% (p<0.001) on the LCS-12 and 27% (p<0.001) on the LKS-7, with significant improvement on questions regarding false-positive and false-negative findings, incidental findings, lung cancer-specific mortality benefit, and the possible harms of screening. Participants reported low scores on the decisional conflict scale (median score 0, IQR 0-5) and high acceptability. Ninety percent ultimately underwent screening within one month of the visit.
INTERPRETATION CONCLUSIONS
This HIV-adapted and personally tailored decision aid improved participants' knowledge of risks, benefits, and characteristics of screening with low decisional conflict and high acceptability. This decision aid can enable high-quality shared decision-making in this high-risk population.

Identifiants

pubmed: 39084517
pii: S0012-3692(24)04876-1
doi: 10.1016/j.chest.2024.07.147
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Nicholas R Murphy (NR)

Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington Department of Medicine, Seattle, WA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: nrmurphy@uw.edu.

Kristina Crothers (K)

Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington Department of Medicine, Seattle, WA; Veterans Affairs Puget Sound Healthcare System, Seattle, WA.

Madison Snidarich (M)

Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.

Jehan Z Budak (JZ)

Division of Allergy and Infectious Diseases, University of Washington Department of Medicine, Seattle, WA.

Meagan C Brown (MC)

Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA; Kaiser Permanente Washington Health Research Institute, Seattle, WA; Department of Epidemiology, University of Washington School of Public Health, Seattle, WA.

Bryan J Weiner (BJ)

Department of Global Health, University of Washington School of Public Health, Seattle, WA; Department of Health Services, University of Washington School of Public Health, Seattle, WA.

Nicholas Giustini (N)

Division of Hematology & Oncology, University of Washington Department of Medicine, Seattle, WA.

Tanner Caverly (T)

Department of Learning Health Sciences, University of Michigan, Ann Arbor VA Center for Clinical Management Research.

Katherine Durette (K)

Advanced Registered Nurse Practitioner, Fred Hutchinson Cancer Center; Teaching Associate, Division of Hematology and Oncology, University of Washington School of Medicine.

Katie DeCell (K)

Advanced Registered Nurse Practitioner, Fred Hutchinson Cancer Center; Teaching Associate, Division of Hematology and Oncology, University of Washington School of Medicine.

Matthew Triplette (M)

Division of Pulmonary, Critical Care and Sleep Medicine, University of Washington Department of Medicine, Seattle, WA; Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA.

Classifications MeSH